These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 22908061)
21. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis. Herac M; Niederle B; Raderer M; Krebs M; Kaserer K; Koperek O APMIS; 2016 Oct; 124(10):839-45. PubMed ID: 27539746 [TBL] [Abstract][Full Text] [Related]
22. Evidence for Somatostatin receptor 2 in thyroid tissue. Druckenthaner M; Schwarzer C; Ensinger C; Gabriel M; Prommegger R; Riccabona G; Decristoforo C Regul Pept; 2007 Jan; 138(1):32-9. PubMed ID: 16996150 [TBL] [Abstract][Full Text] [Related]
23. Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity. Czepczyński R; Matysiak-Grześ M; Gryczyńska M; Bączyk M; Wyszomirska A; Stajgis M; Ruchała M Arch Immunol Ther Exp (Warsz); 2015 Apr; 63(2):147-54. PubMed ID: 25403743 [TBL] [Abstract][Full Text] [Related]
24. Somatostatin receptor 2 expression determined by immunohistochemistry in cold thyroid nodules exceeds that of hot thyroid nodules, papillary thyroid carcinoma, and Graves' disease. Sancak S; Hardt A; Singer J; Klöppel G; Eren FT; Güllüoglu BM; Sen LS; Sever Z; Akalin NS; Eszlinger M; Paschke R Thyroid; 2010 May; 20(5):505-11. PubMed ID: 20450431 [TBL] [Abstract][Full Text] [Related]
25. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773 [TBL] [Abstract][Full Text] [Related]
26. Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Pisarek H; Stepień T; Kubiak R; Borkowska E; Pawlikowski M Thyroid Res; 2009 Jan; 2(1):1. PubMed ID: 19173713 [TBL] [Abstract][Full Text] [Related]
27. Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney. Bhandari S; Watson N; Long E; Sharpe S; Zhong W; Xu SZ; Atkin SL J Histochem Cytochem; 2008 Aug; 56(8):733-43. PubMed ID: 18443363 [TBL] [Abstract][Full Text] [Related]
28. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Buscail L; Saint-Laurent N; Chastre E; Vaillant JC; Gespach C; Capella G; Kalthoff H; Lluis F; Vaysse N; Susini C Cancer Res; 1996 Apr; 56(8):1823-7. PubMed ID: 8620499 [TBL] [Abstract][Full Text] [Related]
29. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting. Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940 [TBL] [Abstract][Full Text] [Related]
30. Differential expression of somatostatin receptor subtype 1-5 proteins in numerous human normal tissues. Unger N; Ueberberg B; Schulz S; Saeger W; Mann K; Petersenn S Exp Clin Endocrinol Diabetes; 2012 Sep; 120(8):482-9. PubMed ID: 22976314 [TBL] [Abstract][Full Text] [Related]
31. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Nasir A; Stridsberg M; Strosberg J; Su PH; Livingston S; Malik HA; Kelley ST; Centeno BA; Coppola D; Malafa ME; Yeatman TJ; Kvols LK Cancer Control; 2006 Jan; 13(1):52-60. PubMed ID: 16508627 [TBL] [Abstract][Full Text] [Related]
37. [Somatostatin receptor status in non-medullary thyroid carcinoma]. Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777 [TBL] [Abstract][Full Text] [Related]
38. Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma. Kong G; Hofman MS; Murray WK; Wilson S; Wood P; Downie P; Super L; Hogg A; Eu P; Hicks RJ J Pediatr Hematol Oncol; 2016 Mar; 38(2):87-96. PubMed ID: 26296147 [TBL] [Abstract][Full Text] [Related]
39. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma. Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564 [TBL] [Abstract][Full Text] [Related]
40. The therapeutic value of SST-A octreotide alone or with adjuvant treatment in patients with advanced medullary thyroid carcinoma and positive (111)In-octreotide scan. Vainas I; Drimonitis A; Boudina M; Kaprara A; Iakovou I; Salem N; Koussis C Hell J Nucl Med; 2005; 8(1):43-7. PubMed ID: 15886753 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]